Researching IPF after her late husband's diagnosis meant learning many new acronyms and abbreviations, says guest writer.

Inhaled lipid nanoparticles loaded with two medicines reduced IPF lung stiffness and fibrosis in mice, outperforming an ...

As an organ recipient, columnist Sam Kirton honors donors and their families each year by decorating holiday trees in the ...

As my husband Donnie’s diagnosis of pulmonary fibrosis (PF) slowly unfolded, I found myself oscillating between anger, sorrow, and disbelief. At the time his symptoms appeared, he was only in his 30s.

Columnist Samuel Kirton attended the Pulmonary Fibrosis Foundation's Summit 2025, where the group's five-year strategic plan was unveiled.

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

The Phase 3 REBUILD clinical trial, which tested Bellerophon Therapeutics‘ inhaled nitric oxide therapy INOpulse in people with pulmonary fibrosis at risk of developing pulmonary hypertension, failed ...